295 related articles for article (PubMed ID: 32253054)
21. Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects.
Israel S; Kumar A; DeAngelis K; Aurivillius M; Dorinsky P; Roche N; Usmani OS
Eur J Pharm Sci; 2020 Oct; 153():105472. PubMed ID: 32682074
[TBL] [Abstract][Full Text] [Related]
22. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
23. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Usmani O; Roche N; Wahab E; Israel S; Jenkins M; Trivedi R; Dorinsky P; Aurivillius M
Respir Res; 2021 Oct; 22(1):261. PubMed ID: 34620167
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant.
Rony F; Cortellini M; Guasconi A; Mathews KS; Piccinno A; Poli G; Vanhoutte F; Klein J
Pulm Pharmacol Ther; 2024 Jun; 85():102299. PubMed ID: 38663512
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
[TBL] [Abstract][Full Text] [Related]
26. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential.
Aurivillius M; Bednarczyk A; Kokot M; Madriaga J; Mei J; Collison K; Surujbally R; Archbell J; Joshi V; Gillen M
Pulm Pharmacol Ther; 2023 Dec; 83():102245. PubMed ID: 37607661
[TBL] [Abstract][Full Text] [Related]
27. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P
AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
[TBL] [Abstract][Full Text] [Related]
29. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
[TBL] [Abstract][Full Text] [Related]
30. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
31. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
Taylor G; Warren S; Dwivedi S; Sommerville M; Mello L; Orevillo C; Maes A; Martin UJ; Usmani OS
Eur J Pharm Sci; 2018 Jan; 111():450-457. PubMed ID: 29055732
[TBL] [Abstract][Full Text] [Related]
32. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
Rabe KF; Martinez FJ; Singh D; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
Ther Adv Respir Dis; 2021; 15():17534666211034329. PubMed ID: 34428980
[TBL] [Abstract][Full Text] [Related]
33. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
34. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
36. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
[TBL] [Abstract][Full Text] [Related]
37. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
39. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
40. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
